Expression And Correlation Study Of PTEN And MDM2 In Bladder Transitional Cell Carcinoma

Objective It is to approach the genes expression and relationship between anti-oncogene PTEN and oncogene MDM2 in bladder transitional cell carcinoma(BTCC) and their clinical significance. Thus provide theory evidence for cancer gene therapy and antitumor drug research, brings new hope to cancer treatment.Methods 65 cases of specimens from patients with bladder transitional cell carcinoma were selected, and in another 10 cases of normal bladder tissue specimens were selected as control. All specimens preoperative without radiotherapy.and chemotherapy or immune therapy. All the specimens is fixed by formaldehyde, embedded by paraffin,5 muon m thick serial section. Applying SP immunohistochemical method to detect the gene expression of the PTEN and MDM2 in the specimens. Statistical analysis of experimental data is used by SPSS 13.0 software. P<0.05 to have significant differences as to inspection standards.Result The positive rate of PTEN in human transitional cell carcinoma group was 47.69%(31/65), with the pathological grade and the clinical stage being higher, the lower expression of PTEN showed(P<0.05); in 10 cases of normal bladder tissue, the positive expression rate of PTEN was 100%. The positive rate of MDM2 was 69.23%(45/65), the higher the pathological grade and the clinical stage were, the lower expression of MDM2 showed(P<0.05); MDM2 didn't express in normal bladder tissue. The expression of PTEN was negatively correlated that of MDM2 in BTCC (r=-0.42, P<0.05). Conclusion The abnormal expression of PTEN and MDM2 plays an important role during the progress of carcinoma, Observe both expression status has significance for early diagnosis, prognosis and guiding treatment of BTCC.